WHO's New Guidelines on HIV Care Call for Earlier Treatment

The new advice could make three to five million more people eligible to take antiretroviral drugs















Share on Tumblr

WHO-HIV-earlier-treatment

JUMPSTARTING TREATMENT: New WHO guidelines could mean that more HIV-patients get treatment before they get sick. Image: ISTOCKPHOTO/JUSUN

The World Health Organization is now advising health care professionals to start patients with HIV on antiretroviral drugs earlier in the course of their infection, as part of new agency guidelines announced Monday.

The new recommendations will likely result in more patients worldwide obtaining treatment, based on their CD4 immune cells counts. Instead of a CD4 cell count of 200, the threshold which the WHO recommended in its 2006 guidelines for HIV treatment, a CD4 cell count at or below 350 should be the cutoff, the agency now advises. In practice, this shift would mean treating HIV-infected patients one or two years earlier. For patients with symptoms of HIV infection, such as weight loss, fever and frequent opportunistic infections, the WHO advises that treatment start immediately, regardless of CD4 count.

Although earlier treatment increases the likelihood of drug side effects and the emergence of drug-resistant viruses, doctors and scientists on the WHO panel for the new guidelines think these risks are outweighed by benefits, namely reducing AIDS-related illnesses and the transmission of HIV. By reducing viral loads in patients, antiretroviral drugs make transmission less likely.

The WHO's guidelines put the worldwide standard for HIV therapy, and in particular in Africa, in step with that of the United States and Europe, where HIV-positive patients with CD4 cell counts of 350 typically are started on therapy.

In creating the new guidelines, which the organization revisits every couple of years, the WHO panel considered national guidelines and international guidelines, as well as relevant clinical studies, says Dr. Siobhan Crowley, who led the WHO's guideline revision process this year. One of the studies, published in 2008, suggested that patients whose antiretroviral treatment was deferred until their CD4 cell counts were below 250 were at greater risk of opportunistic infection than those that received antiretroviral treatment when CD4 cell counts were higher than 350.

Currently, about four million people worldwide are on antiretroviral drugs with another 5.5 million HIV-positive people awaiting treatment. If countries adopt these guidelines, an additional three to five million people would become eligible to take these drugs, according to the WHO's estimate. Partly because patients do not start to feel sick until their CD4 counts drop to around 200, "over half of those [three to five million] still don't know they have HIV," Crowley says

To raise health awareness, the WHO has been recommending increased HIV testing and monitoring of CD4 levels. Under the new guidelines, HIV-positive patients should have their CD4 levels checked every three to six months, as is the policy in the United States and Europe.

But regular CD4 count monitoring is no trivial matter in many areas of Africa where clinics and trained staff are in low supply and transportation is difficult, says David Ross, a clinical epidemiologist at the London School of Hygiene and Tropical Medicine. "For the guidelines to really be implemented, one's going to have to put in place systems to help people come [to the clinic] to have CD4 count tests," he says.

In spite of the work ahead, Ross agrees with the guidelines. "I think it's the right advice. The big question is, 'Will the money come in?'"

Dr. Crowley says that the WHO will not yet give estimates for the price tag of implementing the new guidelines. The organization asks that each country consider what it can afford and what capacity of treatment it can handle. "Many countries have gone to a sort of middle ground. They've gone to 250 [as the CD4 count cutoff]," she says.



2 Comments

Add Comment
View
  1. 1. jpuah23 01:30 PM 12/7/09

    There are many natural ways to rid your body of HIV. In contrast with the traditional antiviral cocktails of medicine today, which cost thousands, have severe side effects, and comes with the double edged sword delema,meaning if the virus doesn’t kill you the cocktails will, this medicine is all natural.Please visit this site for the full information about this subject……http://pushgood-nomorehiv.blogspot.com/

    Reply | Report Abuse | Link to this
  2. 2. jpuah23 01:31 PM 12/7/09

    There are many natural ways to rid your body of HIV. In contrast with the traditional antiviral cocktails of medicine today, which cost thousands, have severe side effects, and comes with the double edged sword delema,meaning if the virus doesn’t kill you the cocktails will, this medicine is all natural.Please visit this site for the full information about this subject……http://pushgood-nomorehiv.blogspot.com/

    Reply | Report Abuse | Link to this
Leave this field empty

Add a Comment

You must sign in or register as a ScientificAmerican.com member to submit a comment.
Click one of the buttons below to register using an existing Social Account.

More from Scientific American

See what we're tweeting about

Scientific American Editors

Tweets could not be retrieved at this time

Free Newsletters


Get the best from Scientific American in your inbox

Solve Innovation Challenges

Powered By: Innocentive

  SA Digital
  SA Digital

Science Jobs of the Week

Email this Article

WHO's New Guidelines on HIV Care Call for Earlier Treatment

X
Scientific American MIND iPad

Tap into your MIND

Get Both Print & Tablet Editions for one low price!

Subscribe Now >>

X

Please Log In

Forgot: Password

X

Account Linking

Welcome, . Do you have an existing ScientificAmerican.com account?

Yes, please link my existing account with for quick, secure access.



Forgot Password?

No, I would like to create a new account with my profile information.

Create Account
X

Report Abuse

Are you sure?

X

Institutional Access

It has been identified that the institution you are trying to access this article from has institutional site license access to Scientific American on nature.com. To access this article in its entirety through site license access, click below.

Site license access
X

Error

X

Share this Article

X